戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 on with modified FOLFIRINOX in patients with metastatic pancreatic cancer.
2 tabine in patients with locally advanced and metastatic pancreatic cancer.
3 cooperates with Kras(G12D) to promote highly metastatic pancreatic cancer.
4 inotecan, and fluorouracil) in patients with metastatic pancreatic cancer.
5 e than with gemcitabine alone in advanced or metastatic pancreatic cancer.
6 proved by the FDA for gemcitabine-refractory metastatic pancreatic cancer.
7 th previously untreated, locally advanced or metastatic pancreatic cancer.
8 therapy in patients with locally advanced or metastatic pancreatic cancer.
9 atment for inoperable, locally advanced, non-metastatic pancreatic cancer.
10 t compared with gemcitabine in patients with metastatic pancreatic cancer.
11 sus gemcitabine monotherapy in patients with metastatic pancreatic cancer.
12  multicenter phase II trial in patients with metastatic pancreatic cancer.
13 t gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer.
14 d first-line options in locally advanced and metastatic pancreatic cancer.
15 rinotecan have similar antitumor activity in metastatic pancreatic cancer.
16 ity in patients with gemcitabine-refractory, metastatic pancreatic cancer.
17  recommendations for second-line therapy for metastatic pancreatic cancer.
18 abine/platinum regimens for the treatment of metastatic pancreatic cancer.
19 with chemotherapy-naive, locally advanced or metastatic pancreatic cancer.
20 tivity in patients with previously untreated metastatic pancreatic cancer.
21 usly untreated patients with unresectable or metastatic pancreatic cancer.
22 in vivo in mouse models of lung fibrosis and metastatic pancreatic cancer.
23 utation mediated the objective regression of metastatic pancreatic cancer.
24 patients (HR, 0.46 [95% CI, 0.27-0.77]) with metastatic pancreatic cancer.
25  and its upstream activators are elevated in metastatic pancreatic cancer.
26 from three separate cohorts of patients with metastatic pancreatic cancer.
27 ing CTCs from blood samples of patients with metastatic pancreatic cancer.
28 ents with unresectable, locally advanced, or metastatic pancreatic cancer.
29 esponse was observed in another patient with metastatic pancreatic cancer.
30 well-tolerated prodrugs with selectivity for metastatic pancreatic cancers.
31 ed and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic in
32  responses in less than 10% of patients with metastatic pancreatic cancer and has a very limited impa
33           Five patients died of recurrent or metastatic pancreatic cancer at 60, 61, 62, 64, and 64 m
34 dullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-di
35 tastatic breast cancer, multiple myeloma, or metastatic pancreatic cancer between January 1, 2017, an
36  superior to gemcitabine in the treatment of metastatic pancreatic cancer, but standard of care remai
37 ults demonstrate a new strategy for treating metastatic pancreatic cancer by inhibiting cholesterol e
38  in response to NT was determined in L3.6, a metastatic pancreatic cancer cell line.
39 ne, urokinase-type plasminogen activator, in metastatic pancreatic cancer cell lines.
40 ctate efflux was also a trait in lung-homing metastatic pancreatic cancer cells, suggesting that lact
41  to investigate the origins and evolution of metastatic pancreatic cancer cells.
42 C16) as a novel selectin ligand expressed by metastatic pancreatic cancer cells.
43 s modified FOLFOX (mFOLFOX) in patients with metastatic pancreatic cancer for whom gemcitabine-based
44 ree DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT0
45  options are now available for patients with metastatic pancreatic cancer, informed by positive resul
46 ong religious belief in a miraculous cure of metastatic pancreatic cancer is used to explore how bett
47 urred in a patient with advanced, refractory metastatic pancreatic cancer lasting 7 months.
48 livery of the nanoparticles into primary and metastatic pancreatic cancer lesions.
49 ial of BB2-30F alone and with gemcitabine in metastatic pancreatic cancer models.
50 describe the generation of a progressive and metastatic pancreatic cancer mouse model after the somat
51                                              Metastatic pancreatic cancer (mPC) still harbors a disma
52 (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC).
53 d metastatic breast cancer (three patients), metastatic pancreatic cancer (one patient), or cysts (on
54 openia is associated with longer survival in metastatic pancreatic cancer patients.
55 therapy is mostly palliative in advanced and metastatic pancreatic cancer patients.
56  implications for current clinical trials on metastatic pancreatic cancer patients.
57 o provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendatio
58 irect association of the MUC4 mucin with the metastatic pancreatic cancer phenotype and provides expe
59                                  Surgery for metastatic pancreatic cancer remains controversial as th
60                            Future studies in metastatic pancreatic cancer should assess the combinati
61 termine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabin
62 ion should be offered treatment per the ASCO Metastatic Pancreatic Cancer Treatment Guideline.
63                   A patient with progressive metastatic pancreatic cancer was treated with a single i
64     Applying macsGESTALT to a mouse model of metastatic pancreatic cancer, we recover ~380,000 CRISPR
65 -three patients with gemcitabine-refractory, metastatic pancreatic cancer were treated continuously w
66  Thirty patients with gemcitabine-refractory metastatic pancreatic cancer were treated with capecitab
67                  We previously reported that metastatic pancreatic cancers were dependent on the gluc
68 ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with antica
69  double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatme
70 Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chem
71                    These lesions progress to metastatic pancreatic cancer with high frequency.
72 equent death of these mice from invasive and metastatic pancreatic cancer with mixed histologic chara